FULC
USDFulcrum Therapeutics Inc. Common Stock
실시간 가격
가격 차트
핵심 지표
시장 지표
시가
$8.830
고가
$9.020
저가
$8.300
거래량
0.37M
기업 기본 정보
시가총액
453.0M
산업
생명공학
국가
United States
거래 통계
평균 거래량
0.53M
거래소
NGM
통화
USD
52주 범위
관련 뉴스
Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
― Pociredir Phase 1b PIONEER Trial Data in Sickle Cell Disease to be Presented and Published, Including 12 mg and 20 mg Cohorts ― ― Live and Webcast Investor Event with Fulcrum Leadership and Medical Experts will be
RBC Capital Maintains Sector Perform on Fulcrum Therapeutics, Raises Price Target to $7
RBC Capital analyst Luca Issi maintains Fulcrum Therapeutics with a Sector Perform and raises the price target from $5 to $7.
Piper Sandler Reiterates Overweight on Fulcrum Therapeutics, Raises Price Target to $16
Piper Sandler analyst Edward Tenthoff reiterates Fulcrum Therapeutics with a Overweight and raises the price target from $12.5 to $16.
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025
― Announced encouraging results in July 2025 from the 12 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― Enrollment complete in the 20 mg dose cohort (n=12) of the
Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET
CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the "Company") (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives
